Single-cell profiling of tuberculosis lung granulomas reveals functional lymphocyte signatures of bacterial control
By
Hannah Priyadarshini Gideon,
Travis K Hughes,
Marc H Wadsworth,
Ang A. Tu,
Todd M Gierahn,
Forrest H Hopkins,
Jun-Rong Wei,
Conner Kummerlowe,
Nicole L Grant,
Kievershen Nargan,
JiaYao Phuah,
H. Jacob Borish,
Pauline Maiello,
Alexander G White,
Sharie Keanne C Ganchua,
Amy Myers,
Cassaundra Ameel,
Catherine T. Cochran,
Sarah K. Nyquist,
Joshua Mark Peters,
Jaime A. Tomko,
Lonnie James Frye,
Jacob Rosenberg,
Angela Shih,
Michael Chao,
Charles Scanga,
Jose Ordovas-Montanes,
Bonnie Berger,
Joshua T Mattila,
Rajhmun Madansein,
J.Christopher Love,
Bryan D Bryson,
Philana Ling Lin,
Alasdair Leslie,
Samuel M. Behar,
JoAnne L Flynn,
Sarah M Fortune,
Alex K Shalek
Posted 26 Oct 2020
bioRxiv DOI: 10.1101/2020.10.24.352492
In humans and nonhuman primates, Mycobacterium tuberculosis lung infection yields a complex multicellular structure: the tuberculosis granuloma. All granulomas are not equivalent, however, even within the same host: in some, local immune activity promotes bacterial clearance, while in others, it allows persistence or outgrowth. Here, we used single-cell RNA-sequencing to define holistically cellular responses associated with control in cynomolgus macaques. Granulomas that facilitated bacterial killing contained significantly higher proportions of CD4+ and CD8+ T cells expressing hybrid Type1-Type17 immune responses or stem-like features and CD8-enriched T cells with specific cytotoxic functions; failure to control correlated with mast cell, plasma cell and fibroblast abundance. Co-registering these data with serial PET-CT imaging suggests that a degree of early immune control can be achieved through cytotoxic activity, but that more robust restriction only arises after the priming of specific adaptive immune responses, defining new targets for vaccination and treatment. ### Competing Interest Statement A.K.S. reports compensation for consulting and/or SAB membership from Merck, Honeycomb Biotechnologies, Cellarity, Cogen Therapeutics, Ochre Bio, and Dahlia Biosciences. CL: shareholder and consultant Honeycomb biotechnologies.
Download data
- Downloaded 1,035 times
- Download rankings, all-time:
- Site-wide: 19,901
- In immunology: 579
- Year to date:
- Site-wide: 7,155
- Since beginning of last month:
- Site-wide: 6,549
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!